drugset / Trial / NCT05147259

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HR011408 at Two Formulations in Healthy Subject

NCT05147259

Phase 1 Completed 62 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedCrossoverDouble-blindTreatment

Summary

The objective of the study is to assess the safety, tolerability and pharmacokinetics of HR011408 at two formulations in healthy subject.

Timeline

Start
2021-11-26
Primary completion
2022-01-22
Completion
2022-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject HR011408 Unknown Subcutaneous